Korro Bio (NASDAQ:KRRO - Get Free Report) had its target price hoisted by research analysts at HC Wainwright from $100.00 to $115.00 in a report released on Friday, MarketBeat reports. The brokerage presently has a "buy" rating on the stock. HC Wainwright's price objective would suggest a potential upside of 43.68% from the company's previous close.
Several other brokerages have also recently issued reports on KRRO. Royal Bank of Canada restated an "outperform" rating and set a $95.00 target price on shares of Korro Bio in a research report on Thursday, September 19th. William Blair initiated coverage on Korro Bio in a research report on Wednesday, August 14th. They set an "outperform" rating and a $180.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $138.00.
View Our Latest Stock Report on KRRO
Korro Bio Price Performance
Korro Bio stock traded up $0.03 during midday trading on Friday, reaching $80.04. 160,650 shares of the stock traded hands, compared to its average volume of 63,133. The stock's fifty day moving average is $42.25 and its 200-day moving average is $47.79. Korro Bio has a 12 month low of $9.15 and a 12 month high of $98.00.
Korro Bio (NASDAQ:KRRO - Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported ($2.43) EPS for the quarter, missing analysts' consensus estimates of ($2.39) by ($0.04). On average, research analysts expect that Korro Bio will post -10.09 EPS for the current fiscal year.
Insider Buying and Selling
In other Korro Bio news, CFO Vineet Agarwal sold 10,216 shares of the firm's stock in a transaction dated Thursday, October 17th. The shares were sold at an average price of $78.26, for a total value of $799,504.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 16.80% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Korro Bio
Several hedge funds and other institutional investors have recently modified their holdings of KRRO. Brown Brothers Harriman & Co. purchased a new position in Korro Bio during the 2nd quarter valued at $28,000. Lynx1 Capital Management LP bought a new stake in shares of Korro Bio during the second quarter worth $129,000. Rhumbline Advisers purchased a new stake in shares of Korro Bio during the second quarter valued at $279,000. Bank of New York Mellon Corp bought a new position in shares of Korro Bio in the second quarter worth about $649,000. Finally, Tri Locum Partners LP purchased a new position in Korro Bio in the 2nd quarter worth about $2,419,000. 13.18% of the stock is currently owned by hedge funds and other institutional investors.
About Korro Bio
(
Get Free Report)
Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
See Also
Before you consider Korro Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Korro Bio wasn't on the list.
While Korro Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
